Lipigon announces development and license agreement with Leaderna for its drug candidate Lipisense®

This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.

Lipigon Pharmaceuticals (Lipigon), a clinical-stage biotech company specializing in lipid biology and with expertise in the field, announced today that it has entered into a development and licensing agreement with Leaderna Therapeutics Ltd (Leaderna) regarding Lipigon's clinical-stage drug candidate Lipisense® in Greater China.

Leaderna will be responsible for the development and commercialization of Lipisense® in mainland China, Hong Kong, Taiwan, and Macau (collectively known as Greater China). Lipigon will retain the global development and commercial rights outside of Greater China. As part of the agreement, Lipigon will receive an upfront payment and may receive milestone payments plus royalties on sales in Greater China up to a total of USD $91 million.

"We are delighted with the agreement and look forward to collaborating with Leaderna on the future development of Lipisense®. This agreement confirms the value of Lipisense® and solidifies Lipigon's leading position in the field of ANGPTL4 drug development. Our collaboration with Leaderna will enable us to fully explore the potential of Lipisense®," says Dr. Stefan K. Nilsson, Chief Executive Officer of Lipigon.

Dr. Stefan K. Nilsson continues, "The next step in the development of Lipisense® is the completion of the Phase I study within a few weeks. Following this milestone, our goal is to achieve a seamless and smooth transition into Phase II."

"Targeting ANGPTL4 with organ-specificity holds great potential in the treatment of lipid metabolism disorders, diabetes, and cardiovascular diseases. Lipisense®, the world's first liver-targeted oligonucleotide molecule to enter Phase I clinical trials, has demonstrated excellent development potential. We are excited to closely collaborate with Lipigon to accelerate the clinical development progress of Lipisense®, reduce clinical risks, and continuously explore the clinical value of Lipisense®," says Dr. Jinqiao Wan, Chairman and Chief Executive Officer of Leaderna.

Dr. Jinqiao Wan adds, "We believe that the collaboration between Leaderna and Lipigon will leverage the strengths of both parties in the field of small nucleotide drug development, benefiting patients worldwide and in the Greater China region at an early stage."

About Lipisense®
Lipisense® is an investigational antisense medicine designed to reduce the production of ANGPTL4 protein in the liver. ANGPTL4 has a strong genetic association with plasma lipid levels and related diseases such as cardiovascular disease and type 2 diabetes. Lipisense® is currently being evaluated in a Phase 1 study in healthy volunteers.

About Leaderna
Leaderna Therapeutics Ltd. (Leaderna), a spin-off of HitGen Inc. (682222.SH), was established in July 2022 to focus on pioneering research and development of synthetic oligonucleotide therapeutics. Leveraging its advanced siRNA design, modification, evaluation, and delivery platform, Leaderna has successfully established a robust pipeline targeting metabolism, cardiovascular diseases, and inflammation.

For more information, please contact:
Stefan K. Nilsson, CEO, Lipigon
Email: [email protected]
Phone: +46 705 78 17 68

This is information that Lipigon Pharmaceuticals AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 am CET, on 27 June 2023.

About Lipigon
Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigons initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigons pipeline includes four active projects: the RNA-drug Lipisense® for the treatment of hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Om Lipigon



Få löpande information från Lipigon via e-post.


Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn LPGO ISIN-kod SE0015382072 Certified Adviser G&W Fondkommission


Stefan K. Nilsson VD [email protected] +46 70 578 17 68